Previous Article | Next Article ![]()
Infection and Immunity, February 1999, p. 782-788, Vol. 67, No. 2
Center for Vaccine Development, University of
Maryland School of Medicine, Baltimore, Maryland 21201
Received 31 July 1998/Returned for modification 1 October
1998/Accepted 17 November 1998
Based upon the lipopolysaccharide (LPS) structure and antigenicity
of Shigella group B, a strategy for broad cross-protection against 14 Shigella flexneri serotypes was designed. This
strategy involves the use of two S. flexneri serotypes
(2a and 3a), which together bear the all of the major antigenic group
factors of this group. The novel attenuated strains used in these
studies were S. flexneri 2a strain CVD 1207 (
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Strategy for Cross-Protection among Shigella
flexneri Serotypes
guaB-A
virG
set1
sen) and S. flexneri 3a strain CVD 1211 (
guaB-A
virG
sen). Guinea pigs were immunized with an equal mixture of
these strains and later challenged (Sereny test) with a wild-type
S. flexneri serotype 1a, 1b, 2b, 4b, 5b, Y, or 6 strain of demonstrated virulence in the same model. Guinea pigs that
were immunized with these two vaccine strains produced serum and
mucosal antibodies that cross-reacted with all the S. flexneri serotypes tested (except of S. flexneri serotype 6) as assessed by enzyme-linked immunosorbent assay, immunoblotting, and slide agglutination. Furthermore, the combination vaccine conferred significant protection against challenge with S. flexneri serotypes 1b, 2b, 5b, and Y but not with
serotypes 1a, 4b, or (as predicted) 6.
*
Corresponding author. Present address: Clinical
Development, Pasteur Mérieux Connaught, Discovery Drive,
Swiftwater, PA 18370-0187. Phone: (717) 839-6188. Fax: (717) 839-0934. E-mail: fnoriega{at}us.pmc-vacc.com.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|